NLRP3 and diabetic kidney disease: Diabetic nephropathy also involves NLRP3 inflammasome-induced inflammation, but supplementation with (−)-epigallocatechin gallate reduced the expression of ER stress markers and NLRP3 inflammasome components, implying that (−)-epigallocatechin gallate has anti-inflammatory effects that are principally exerted through the inhibition of endoplasmic reticulum stress and NLRP3.